Endometriosis Approved Drugs
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Endometriosis.
Found 6 Approved Drugs for Endometriosis
Danazol
Generic Name
Danazol
Danazol
Generic Name
Danazol
Form: Capsule
Method of administration: Oral
FDA approval date: August 09, 1996
Classification: Androgen
Endometriosis. Danazol capsules are indicated for the treatment of endometriosis amenable to hormonal management. Hereditary Angioedema. Danazol capsules are indicated for the prevention of attacks of angioedema of all types (cutaneous, abdominal, laryngeal) in males and females.
Norethindrone Acetate
Brand Names
24FE, Nylia, Sharobel, Taysofy, Hailey 24, Tarina, Vyfemla, Deblitane, Wymzya, Aurovela, Mibelas 24, Lyleq, Etyqa, Merzee, Gallifrey, Junel 21, Microgestin 24, Affodel, Femlyv, Philith, Aranelle, Dasetta, Necon, Fyavolv, Mimvey, Nortrel 28, Zenchent, Lopreeza, Balziva, Xelria, OSHIH, Emzahh, Leena, Loestrin 21, Activella, Norethindrone, Junel, Camila, Taytulla, Layolis, Cyonanz, Blisovi 24, Loestrin, Feirza, Tarina 24, Briellyn, Tri-Legest, Melodetta 24, Jinteli, Aurovela 24, Wera, Galbriela, Microgestin, Myfembree, Nortrel, Blisovi, ERRIN, Alyacen, Finzala, Meleya, Kaitlib, Nortrel 21, Orquidea, Rhuzdah, Nexesta, Incassia, XARAH, Jencycla, Hailey
Norethindrone Acetate
Brand Names
24FE, Nylia, Sharobel, Taysofy, Hailey 24, Tarina, Vyfemla, Deblitane, Wymzya, Aurovela, Mibelas 24, Lyleq, Etyqa, Merzee, Gallifrey, Junel 21, Microgestin 24, Affodel, Femlyv, Philith, Aranelle, Dasetta, Necon, Fyavolv, Mimvey, Nortrel 28, Zenchent, Lopreeza, Balziva, Xelria, OSHIH, Emzahh, Leena, Loestrin 21, Activella, Norethindrone, Junel, Camila, Taytulla, Layolis, Cyonanz, Blisovi 24, Loestrin, Feirza, Tarina 24, Briellyn, Tri-Legest, Melodetta 24, Jinteli, Aurovela 24, Wera, Galbriela, Microgestin, Myfembree, Nortrel, Blisovi, ERRIN, Alyacen, Finzala, Meleya, Kaitlib, Nortrel 21, Orquidea, Rhuzdah, Nexesta, Incassia, XARAH, Jencycla, Hailey
Form: Tablet, Kit
Method of administration: Oral
FDA approval date: May 25, 2001
Classification: Progestin
Aurovela.
Zoladex
Generic Name
Goserelin
Zoladex
Generic Name
Goserelin
Form: Implant
Method of administration: Subcutaneous
FDA approval date: January 26, 2018
Classification: Gonadotropin Releasing Hormone Receptor Agonist
ZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for: Use in combination with flutamide for the management of locally confined carcinoma of the prostate.
Synarel
Generic Name
Nafarelin acetate
Synarel
Generic Name
Nafarelin acetate
Form: Spray
Method of administration: Nasal
FDA approval date: February 13, 1990
Classification: Gonadotropin Releasing Hormone Receptor Agonist
FOR CENTRAL PRECOCIOUS PUBERTY (For Endometriosis, See Reverse Side ) SYNAREL is indicated for treatment of central precocious puberty (CPP) (gonadotropin-dependent precocious puberty) in children of both sexes. The diagnosis of central precocious puberty (CPP) is suspected when premature development of secondary sexual characteristics occurs at or before the age of 8 years in girls and 9 years in boys, and is accompanied by significant advancement of bone age and/or a poor adult height prediction. The diagnosis should be confirmed by pubertal gonadal sex steroid levels and a pubertal LH response to stimulation by native GnRH. Pelvic ultrasound assessment in girls usually reveals enlarged uterus and ovaries, the latter often with multiple cystic formations. Magnetic resonance imaging or CT-scanning of the brain is recommended to detect hypothalamic or pituitary tumors, or anatomical changes associated with increased intracranial pressure. Other causes of sexual precocity, such as congenital adrenal hyperplasia, testotoxicosis, testicular tumors and/or other autonomous feminizing or masculinizing disorders must be excluded by proper clinical hormonal and diagnostic imaging examinations. FOR ENDOMETRIOSIS (For Central Precocious Puberty, See Reverse Side ) SYNAREL is indicated for management of endometriosis, including pain relief and reduction of endometriotic lesions. Experience with SYNAREL for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months.
Orilissa
Generic Name
Elagolix
Orilissa
Generic Name
Elagolix
Form: Tablet
Method of administration: Oral
FDA approval date: July 23, 2018
Classification: Gonadotropin Releasing Hormone Receptor Antagonist
ORILISSA is indicated for the management of moderate to severe pain associated with endometriosis. Limitation s of Use: Limit the duration of use based on the dose and coexisting condition [see D osage and Administration.
Showing 1-5 of 6
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances